17.53USD+0.75%Mkt Cap: 419.90M USDP/E: —Last update: 2026-05-22
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmon…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap419.90M USD
Enterprise Value4.14B USD
Revenue (TTM)4.66M USD
Gross Profit-51.80M USD
Net Income (TTM)-109.74M USD
Revenue/Share0.1900 USD
Last Price17.53 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-34.50
PEG—
EV/EBITDA-42.79
EV/Revenue889.38
P/S90.13
P/B1.34
EPS (TTM)-4.60
EPS (Forward)-0.50
52W Range
14.5056% of range19.92
52W High19.92 USD
52W Low14.50 USD
Profitability
Gross Margin0.00%
Oper. Margin-1797.79%
EBITDA Margin0.00%
Profit Margin-2355.42%
ROE-35.16%
ROA-20.52%
Growth
Revenue Growth-38.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-85.13M USD
CapEx (TTM)6.00K USD
FCF Margin-1931.54%
FCF Yield-21.43%
Net Debt-85.46M USD
Net Debt/EBITDA0.88
Balance Sheet
Debt/Equity0.06
Current Ratio6.59
Quick Ratio6.41
Book Value/Sh12.91 USD
Cash/Share1.186 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.24.34M
Float157.18M
Insiders0.00%
Institutions0.58%
Short Interest
Short Ratio3.9d
Short % Float0.12%
Short % Out.0.10%
Shares Short24.52K
Short (prev mo.)14.82K
Technical
SMA 5016.83 (+4.1%)
SMA 20017.24 (+1.7%)
Beta0.79
S&P 52W Chg28.31%
Avg Vol (30d)14.08K
Avg Vol (10d)15.03K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—